Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4,196 Mln
Revenue (TTM)
$488 Mln
Net Profit (TTM)
$0 Mln
ROE
0.2 %
ROCE
-- %
P/E Ratio
87
P/B Ratio
15.7
Industry P/E
61.46
EV/EBITDA
51.1
Div. Yield
0 %
Debt to Equity
1.9
Book Value
$--
EPS
$1.3
Face value
--
Shares outstanding
33,833,800
CFO
$-223.45 Mln
EBITDA
$-179.01 Mln
Net Profit
$-236.41 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
TransMedics Group (TMDX)
| 98.2 | 0.2 | 78.9 | -11.1 | 62.2 | 48.9 | -- |
|
BSE Sensex
| 4.7 | 1.2 | 6.5 | 6.1 | 16.5 | 18.6 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|
|
TransMedics Group (TMDX)
| -20.9 | 27.9 | 222.1 | -3.7 | 4.7 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
TransMedics Group (TMDX)
|
123.6 | 4,195.7 | 488.2 | 49.0 | 11.7 | 20.6 | 87 | 15.7 |
| 13.3 | 9,247.0 | 6,685.2 | 715.6 | 16.4 | 12.3 | 13 | 1.5 | |
| 250.1 | 6,628.2 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 1.0 | |
| 232.6 | 6,325.6 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 0.9 | |
| 97.8 | 5,722.6 | 404.5 | -123.7 | -26.1 | -17.3 | -- | 7.5 | |
| 57.5 | 7,834.4 | 2,510.8 | 185.6 | 8.8 | 4.5 | 43.2 | 1.9 | |
| 71.8 | 8,997.9 | 12,669.0 | 407.0 | 5.4 | 11.8 | 22.4 | 2.7 | |
| 166.0 | 8,955.9 | 1,973.6 | -494.5 | -11.4 | -41 | -- | 9.3 | |
| 252.4 | 9,952.9 | 1,240.1 | 42.2 | 4.1 | 3.6 | 238 | 8.2 | |
| 117.8 | 6,677.4 | 645.7 | -25.4 | 6.8 | -1.3 | -- | 3.6 |
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a... portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. Read more
Founder, President, CEO & Director
Dr. Waleed H. Hassanein M.D.
Founder, President, CEO & Director
Dr. Waleed H. Hassanein M.D.
Headquarters
Andover, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of TransMedics Group Inc (TMDX) stood at $ 893 Mln as on 31-Mar-25
The share price of TransMedics Group Inc (TMDX) is $123.56 (NASDAQ) as of 23-Jun-2025 13:37 EDT. TransMedics Group Inc (TMDX) has given a return of 62.15% in the last 3 years.
TransMedics Group Inc (TMDX) has a market capitalisation of $ 4,196 Mln as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of TransMedics Group Inc (TMDX) is 15.70 times as on 20-Jun-2025, a 346% premium to its peers’ median range of 3.52 times.
The P/E ratio of TransMedics Group Inc (TMDX) is 87.01 times as on 20-Jun-2025, a 42% premium to its peers’ median range of 61.46 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the TransMedics Group Inc (TMDX) and enter the required number of quantities and click on buy to purchase the shares of TransMedics Group Inc (TMDX).
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
The CEO & director of Dr. Waleed H. Hassanein M.D.. is TransMedics Group Inc (TMDX), and CFO & Sr. VP is Dr. Waleed H. Hassanein M.D..
There is no promoter pledging in TransMedics Group Inc (TMDX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
995
|
|
|
906
|
|
|
889
|
|
|
883
|
|
|
777
|
|
|
708
|
|
|
663
|
|
|
663
|
|
|
585
|
| TransMedics Group Inc. (TMDX) | Ratios |
|---|---|
|
Return on equity(%)
|
20.56
|
|
Operating margin(%)
|
11.7
|
|
Net Margin(%)
|
10.03
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of TransMedics Group Inc (TMDX) was $0 Mln.
